Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 7, Issue 10, Pages 559-560Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2010.152
Keywords
-
Categories
Funding
- NCI NIH HHS [P50 CA083639-01, P50 CA083639, 1P50 CA83639] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P50CA083639] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Ovarian cancer that recurs more than 6 months following primary chemotherapy can respond to many different drugs, but retreatment with a combination of carboplatin and paclitaxel has become a standard of care. A combination of pegylated liposomal doxorubicin and carboplatin may provide a slightly, but significantly, greater therapeutic index than carboplatin and paclitaxel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
